Supported by

Catalogue of collaboration profiles

back to list
Company

IMG Innovations-Management GmbH/ Enterprise Europe Network

Street
Kurt-Schumacher Str. 74 a
ZIP Code
67663
City
Kaiserslautern
Country
Germany


Company Profile:
IMG Innovations-Management GmbH is the partner of science and economy in the field of innovation management and Technology Transfer in Germany / Rheinland-Pfalz
IMG has the task to support Technology and Knowledge Transfer between science and economy. Therefore, IMG is the central contact point of innovation management, especially for small and medium-sized innovative enterprises and start-ups

The range of services offered by IMG include the support of

• universities and research organisations in securing their intellectual property rights and in marketing their scientific results and findings;
• free inventors in obtaining property rights and in implementing their innovations
• enterprises in their systematic search for innovative products, services and proceedings.

Furthermore, IMG offers support in
• providing topic-related business contacts, co-operations and technologies;
• the Europe wide consultancy of enterprises and research institutions on latest national and European funding schemes;
• managing initiatives
Profiltitel

IMG-German Enterprise Europe Network Partner

What we offer:
As a partner in Enterprise Europe Network we are ready to give information about the technologies and partnerships offered and required by our local companies and research organisations. If you are looking for clients or technology/research cooperations, we might help you to find them in the southwest of Germany.

What are we looking for:
We are intersted in any cooperation opportunities for our industrial and academic clients.

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Joint Venture Agreement
  • Manufacturing Agreement
  • Licence
  • Commercial Agreement


Responsible

Julia Dohnt-Glander

consultant

Profiltitel

Catheter for treatment of preterm premature rupture of membranes

What we offer:
Preterm premature rupture of membranes (PPROM) is one of the leading causes of perinatal morbidity and mortality. It complicates 3% of pregnancies and is responsible for a third of all preterm births. Repetitive transabdominal amnioinfusions for treatment of PPROM showed low benefit in case of fluid loss within 6h. The successful treatment of PPROM by the use of a subcutaneously implanted Amniotic Fluid Replacement Port System in humans for long-term amnioinfusion was approved twice in patents. In addition, the new technology is improved by a special intrauterine catheter which is characterized by a small diameter and can be placed via a very thin finder needle under ultrasound control. The catheter is fixed by the use of two balloons, which surround the uterus’ wall.

What are we looking for:
The university is looking for Cooperation partners for prototype development, licensing for production and distribution

Collaboration sought:
  • Technical Co-operation
  • Manufacturing Agreement
  • Licence


Responsible

Julia Dohnt-Glander

consultant

Profiltitel

Novel Pharmaceutical Compound Class with Anti-Inflammatory Properties

What we offer:
Selectins (cell adhesion molecules) present functional importance in pathophysiological processes of the immune and cardiovascular systems, which makes them attractive pharmaceutical targets. In the early stage of an immune response an upregulated expression of selectins in endothelial cells causes a deceleration of the flow, a rolling, and eventually an attachment of leukocytes to the endothelium, so that these can subsequently migrate through the endothelium into the tissue. The process of recognition which initiates the mentioned sequence occurs between selectins and the carbohydrate epitopes of glycoproteins. The adhesion processes with subsequent extravasation of leukocytes are crucial for the chronification of inflammatory di¬seases and for cancer metastasis.

What are we looking for:
The university is interested in licence transfer for further development; test samples are available upon request.

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Joint Venture Agreement
  • Licence


Responsible

Julia Dohnt-Glander

consultant

Profiltitel

Heparin Nitroxide Derivatives with Longer-Lasting Antioxidant and Paramagnetic Properties

What we offer:
The formation of free radicals and the effect of these toxic molecules on various cell functions are collectively described as oxidative stress. Oxidative stress results from an inbalance between the formation and neutralization of free radicals within the cell and/or extracellular space.
Heparin Nitroxide Derivatives possess antioxidant and paramagnetic properties and perform the role of a scavenging agent. Therefore they are applicable to the successful treatment of oxidative stress mediated diseases. Additionally they are suitable for diagnostic purposes such as Magnetic Resonance Imaging (MRI) and Electron Paramagnetic Resonance Imaging (EPRI) of the vascular structure of vessels or the monitoring of local vascular oxidative stress in vivo.

What are we looking for:
The university is mainly looking for partners in research cooperation and development;

possibility for exclusive or non-exclusive licensing

Collaboration sought:
  • Research & Development
  • Joint Venture Agreement
  • Licence


Responsible

Julia Dohnt-Glander

consultant

Profiltitel

Catheter for treatment of fetal congenital urinary tract obstruction

What we offer:
Fetal congenital lower urinary tract obstructions affect between 1:250 to 1:1000 pregnancies and are often associated with high perinatal mortality and varying degrees of perinatal and infant morbidity. Affected fetuses have also associated oligo-hydramnios with the development of pulmonary hypoplasia, a scenario almost always associated with perinatal death. For treatment a ’Michael Harrison’ catheter can be inserted for a continuous bladder drainage. This procedure may be associated with maternal and fatal morbidity as the needle for inserting the catheter is unacceptably thick. An aggravating factor is that the fetus himself often pulls out the catheter, leading to repeated implantations. Due to these severe disadvantages, in most cases the disease is not treated at all.

What are we looking for:
The university seeks partners for licensing for production and distribution, Cooperation partners for prototype development are sought-after

Collaboration sought:
  • Technical Co-operation
  • Manufacturing Agreement
  • Licence


Responsible

Julia Dohnt-Glander

consultant

back to list

Participants

Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd


© 2010 ConVerve GmbH | all rights reserved